October 29, 2018 / 6:20 AM / 22 days ago

Roche touts study data as eye disease market primed for shake-up

ZURICH, Oct 29 (Reuters) - Swiss drugmaker Roche on Monday touted data for a new drug against a blindness-causing eye disease that hits millions of older people, the latest sign this multi-billion-dollar market is primed for disruption.

Roche's experimental faricimab, a bispecific antibody, showed potential for extended durability in use against the disease neovascular age-related macular degeneration, it said in a statement. (Reporting by John Miller; Editing by Maria Sheahan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below